(Q39478416)

English

The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1 reference

based on heuristic

inferred from title

author name string

Jung-Mi Lee

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Jeong-Hwan Seo

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Yeon-Jeong Kim

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Yun-Sun Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Hyun-Jeong Ko

5

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Chang-Yuil Kang

6

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

language of work or name

0 references

publication date

20 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

131

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

741-751

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Modulators of arginine metabolism support cancer immunosurveillance

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Generation and maturation of dendritic cells for clinical application under serum-free conditions

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

NKT cells: what's in a name?

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

The biology of NKT cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2'-deoxycytidine

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26411

21 January 2018

Identifiers

10.1002/IJC.26411

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39478416&oldid=1830093032"